FDA application holder
West-ward Pharmaceuticals International Ltd
The Orange Book identifies this organization as the applicant responsible for ANDA 081002.
Orange Book drug · Generic (ANDA)
Meperidine Hydrochloride Preservative Free
Meperidine Hydrochloride
ANDA 081002 West-ward Pharms Int
Approved
Jul 30, 1993
Strengths
1
Listed patents
0
Applications
6
What does the FDA Orange Book show for Meperidine Hydrochloride Preservative Free?
Meperidine Hydrochloride Preservative Free contains Meperidine Hydrochloride and appears in 6 FDA Orange Book applications. ANDA 081002 is the lead filing, with 1 presentation shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.
- FDA applications
- 6; lead ANDA 081002
- Lead application holder
- West-ward Pharmaceuticals International Ltd
- Product presentations
- 1
- Marketing categories
- Prescription
- Reference roles
- RS
- TE codes
- None posted
- Listed patents
- 0
- Exclusivity records
- 0
Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.
The listed applicant holds the FDA application; this field does not establish the product manufacturer.
Each FDA product number remains tied to its own strength, dosage form, route, and status.
Orange Book marketing categories do not establish real-time inventory or commercial availability.
RLD and RS designations are presentation-specific, not inferred from the trade name.
Therapeutic-equivalence codes apply only within the matching Orange Book product heading.
A zero means none appear in this snapshot, not that no patent rights exist.
FDA exclusivity and listed patent protection are distinct regulatory concepts.
Sourced from the official FDA Orange Book data file · snapshot refreshed
FDA product-presentation matrix
Every product number in this exact application
| Product | Strength | Dosage form / route | Marketing status | TE code | Reference role |
|---|---|---|---|---|---|
| 001 | 10MG/ML | INJECTABLEINJECTION | Prescription | None posted | RS |
Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.
Who is responsible for this application?
Application holder is not the same as manufacturer
Manufacturer status
Not established by the Orange Book
A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.
Regulatory interpretation
What the record means, and what it does not
FDA marketing status
1 presentation listed as prescription
RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.
Therapeutic equivalence
No TE code is posted for this application
No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.
Patent & exclusivity record
No listed patents or exclusivity records
This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.
Same-ingredient landscape
36 other ANDAs and 2 other NDAs found
5 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.
Which products are meaningfully comparable?
Exact ingredient + dosage form + route cohorts
ANDA 081002 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.
Injectable · Injection
Meperidine Hydrochloride
- Product rows
- 45
- Active applications
- 4
- Active with AB row
- 0
Why are clinical sections unavailable?
Exact application-label matching status
Exact source match queuedQueue ANDA-081002
No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.
Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.
Product detail
ANDA 081002
RS
- Strength
- 10MG/ML
- Dosage form
- INJECTABLE
- Route
- INJECTION
- Marketing status
- Prescription
Key dates
Approval, patents, exclusivityApproval
FDA approval date of this drug product.
33 yr 6 mo ago
Today
Pharmaceutical detail
FDA product recordActive ingredient
MEPERIDINE HYDROCHLORIDE
Strength
10MG/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
Not listed
Application
ANDA 081002
Product number
001
Marketing status
Prescription
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Listed patents
Orange Book patent fileNo patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Other FDA applications for Meperidine Hydrochloride Preservative Free
5 additional filings · 5 generic
The FDA has approved 6 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.
| Application | Applicant | Approved | Strengths | TE code | Status |
|---|---|---|---|---|---|
| ANDA 088432 | Icu Medical Inc | Aug 16, 1984 | 1 | — | Discontinued |
| ANDA 040163 | Specgx LLC | May 12, 1997 | 1 | — | Discontinued |
| ANDA 040305 | Hospira | Mar 10, 1999 | 1 | — | Discontinued |
| ANDA 073443 | Watson Labs | Mar 17, 1992 | 1 | — | Discontinued |
| ANDA 081309 | Intl Medication | Aug 30, 1993 | 1 | — | Discontinued |
Active-ingredient family
Brand + generics
Generic (ANDA) of Meperidine Hydrochloride
- —DemerolBrand (NDA)
NDA 021171 · Hospira
- —DemerolBrand (NDA)
NDA 005010 · Quagen
- 2009Meperidine HydrochlorideGeneric (ANDA)
ANDA 040893 · Genus
- 2002Meperidine HydrochlorideGeneric (ANDA)
ANDA 040446 · Sun Pharm Inds Inc
- 2000Meperidine HydrochlorideGeneric (ANDA)
ANDA 040352 · Specgx LLC
- 1999Meperidine HydrochlorideGeneric (ANDA)
ANDA 040318 · Duramed Pharms Barr
- 1999Meperidine HydrochlorideGeneric (ANDA)
ANDA 040331 · Epic Pharma LLC
- 1998Meperidine HydrochlorideGeneric (ANDA)
ANDA 040191 · Strides Pharma Intl
- 1997Meperidine HydrochlorideGeneric (ANDA)
ANDA 040186 · Watson Labs
- 1997Meperidine HydrochlorideGeneric (ANDA)
ANDA 040110 · Hikma
- 1992Meperidine HydrochlorideGeneric (ANDA)
ANDA 073444 · Watson Labs
- 1992Meperidine HydrochlorideGeneric (ANDA)
ANDA 073445 · Watson Labs
How to use this record responsibly
Scope, limitations, and primary sources
What to verify before making a decision
- The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
- RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
- Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
- Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
- The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.
Official FDA references
- Electronic Orange Book record
- Orange Book preface and TE-code policy
- FDA product, patent, and exclusivity data files
Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.
Meperidine Hydrochloride Preservative Free: frequently asked questions
Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.
Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of ANDA 081002 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
